US 12,257,237 B2
Tinostamustine for use in treating sarcoma
Thomas Jorg Mehrling, Basel (CH)
Assigned to Purdue Pharma L.P., Stamford, CT (US)
Filed by Purdue Pharma L.P., Stamford, CT (US)
Filed on Feb. 13, 2023, as Appl. No. 18/108,736.
Application 18/108,736 is a continuation of application No. 16/621,885, granted, now 11,576,899, previously published as PCT/EP2018/065668, filed on Jun. 13, 2018.
Claims priority of application No. 1709403 (GB), filed on Jun. 13, 2017.
Prior Publication US 2023/0277507 A1, Sep. 7, 2023
Int. Cl. A61K 31/4184 (2006.01); A61N 5/10 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4184 (2013.01) [A61N 5/10 (2013.01); A61P 35/00 (2018.01)] 20 Claims
 
1. A method of treating a solid tumor in a patient in need thereof, comprising administering to said patient an effective amount of tinostamustine or a pharmaceutically acceptable salt thereof, wherein the solid tumor is selected from the group consisting of: a small cell Lung cancer (SCLC), a soft tissue sarcoma, a bone sarcoma, and a non-KIT gastrointestinal stromal tumour (GIST),
wherein the solid tumor is at a histologically or cytological confirmed extensive disease stage, and is progressing during or relapsing after at least one prior treatment comprising chemotherapy or surgery.